The batch documentation including the endotoxin test, the individual donor protocol, the ikz protocol, the random sample test and the sterilization certificate were reviewed.A discrepancy was found which, however, had no effect on the complaint graft.According to the documentation, the product was therefore manufactured in accordance with the specification.During the trend analysis, 12 comparable complaints with 13 products were found for the same product code.Since this is not a spontaneous report, but an increase in frequency due to the clinical study, there is no trend.Based on the data received and the inspection of the batch documentation, there is no indication of the unsterility of the affected products.Based on the results of this investigation, it is more plausible that the patient's adverse reaction was associated with a source or event extrinsic to the xengraft implant.
|
Rti surgical, inc (rti) and tutogen medical (b)(4), a wholly subsidiary of rti, received a complaint on 06/30/2021, as part of the fortiva appear trial.The reported complaint indicated that a patient was implanted with a fortiva porcine dermis on (b)(6) 2021 and on an unknown date.On (b)(6) 2021, the patient developed seromas.
|